There was, however, division within the panel. Thirteen experts voted in favour, but ten others against. The panel can only give advice, the final decision rests with the American drug watchdog FDA.
–
Test results on Saturday showed that Merck’s drug reduces the risk of hospitalization or death in adults with mild to moderate illness by 30 percent. That is less than the previous estimate of 48 percent.
–
From the analysis of the results announced by Merck, there were nine deaths recorded in the group that received a placebo and one in the group that received the treatment. A total of 1,433 people participated in the study.
–
–
